首页> 外文OA文献 >Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany
【2h】

Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany

机译:药物基因组学和药物遗传学指导的个性化治疗的成本效益:对德国个性化药物批准的活性物质的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: The use of targeted therapies has recently increased. Pharmacogenetic tests are a useful tool to guide patient treatment and to test a response before administering medicines. Pharmacogenetic tests can predict potential drug resistance and may be used for determining genotype-based drug dosage. However, their cost-effectiveness as a diagnostic tool is often debatable. In Germany, 47 active ingredients are currently approved. A prior predictive test is required for 39 of these and is recommended for eight. The objective of this study was to review the cost-effectiveness (CE) of pharmacogenetic test-guided drug therapy and compare the application of drugs with and without prior genetic testing. Methods: A systematic literature review was conducted to identify the CE and cost-utility of genetic tests. Studies from January 2000 until November 2015 were searched in 16 databases including Medline, Embase, and Cochrane. A quality assessment of the full-text publications was performed using the validated Quality of Health Economic Studies (QHES) instrument. Results: In the majority of the included studies, the pharmacogenetic test-guided therapy represents a cost-effective/cost-saving treatment option. Only seven studies lacked a clear statement of CE or cost-savings, because of uncertainty, restriction to specific patient populations, or assumptions for comparative therapy. Moreover, the high quality of the available evidence was evaluated. Conclusion: Pharmacogenetic testing constitutes an opportunity to improve the CE of pharmacotherapy. The CE of targeted therapies depends on various factors including costs, prevalence of biomarkers, and test sensitivity and specificity. To guarantee the CE comparability of stratified drug therapies, national and international standards for evaluation studies should be defined. © 2016, The Author(s).
机译:背景:靶向治疗的使用最近有所增加。药物遗传学测试是指导患者治疗并在给药之前测试反应的有用工具。药物遗传学测试可以预测潜在的耐药性,并可用于确定基于基因型的药物剂量。但是,它们作为诊断工具的成本效益通常值得商bat。在德国,目前已批准47种活性成分。其中39项需要事先进行预测性测试,建议进行8项。这项研究的目的是审查药物遗传学测试指导的药物治疗的成本效益(CE),并比较经过和未经过基因测试的药物的应用。方法:进行了系统的文献综述,以鉴定基因检测的CE和成本效益。 2000年1月至2015年11月的研究在Medline,Embase和Cochrane等16个数据库中进行了检索。使用经验证的卫生经济研究质量(QHES)仪器对全文出版物进行了质量评估。结果:在大多数纳入研究中,药物遗传学测试指导疗法代表了一种具有成本效益/节省成本的治疗选择。由于不确定性,特定患者人群的限制或比较治疗的假设,只有七项研究缺乏明确的CE或节省费用的陈述。此外,对可用证据的高质量进行了评估。结论:药物遗传学检测为改善药物治疗的CE提供了机会。靶向疗法的CE取决于多种因素,包括成本,生物标志物的流行率以及测试的敏感性和特异性。为保证分层药物治疗的CE可比性,应定义评价研究的国家和国际标准。 ©2016,作者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号